vs

Side-by-side financial comparison of KORE Group Holdings, Inc. (KORE) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.

KORE Group Holdings, Inc. is the larger business by last-quarter revenue ($73.9M vs $65.1M, roughly 1.1× MESA LABORATORIES INC). MESA LABORATORIES INC runs the higher net margin — 5.6% vs -25.0%, a 30.6% gap on every dollar of revenue. On growth, MESA LABORATORIES INC posted the faster year-over-year revenue change (3.6% vs 0.7%). MESA LABORATORIES INC produced more free cash flow last quarter ($18.0M vs $9.4M). Over the past eight quarters, MESA LABORATORIES INC's revenue compounded faster (5.1% CAGR vs -1.4%).

KORE Wireless is a publicly traded company that provides IoT connectivity, managed services, and related solutions. The company supports applications across sectors including healthcare, logistics, fleet, utilities, and industrial automation, with more than 20 million active connections reported worldwide.

Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.

KORE vs MLAB — Head-to-Head

Bigger by revenue
KORE
KORE
1.1× larger
KORE
$73.9M
$65.1M
MLAB
Growing faster (revenue YoY)
MLAB
MLAB
+2.9% gap
MLAB
3.6%
0.7%
KORE
Higher net margin
MLAB
MLAB
30.6% more per $
MLAB
5.6%
-25.0%
KORE
More free cash flow
MLAB
MLAB
$8.6M more FCF
MLAB
$18.0M
$9.4M
KORE
Faster 2-yr revenue CAGR
MLAB
MLAB
Annualised
MLAB
5.1%
-1.4%
KORE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
KORE
KORE
MLAB
MLAB
Revenue
$73.9M
$65.1M
Net Profit
$-18.5M
$3.6M
Gross Margin
64.2%
Operating Margin
-0.8%
12.2%
Net Margin
-25.0%
5.6%
Revenue YoY
0.7%
3.6%
Net Profit YoY
27.4%
316.6%
EPS (diluted)
$-0.92
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KORE
KORE
MLAB
MLAB
Q4 25
$73.9M
$65.1M
Q3 25
$68.7M
$60.7M
Q2 25
$71.3M
$59.5M
Q1 25
$72.1M
$62.1M
Q4 24
$73.3M
$62.8M
Q3 24
$68.9M
$57.8M
Q2 24
$67.9M
$58.2M
Q1 24
$76.0M
$58.9M
Net Profit
KORE
KORE
MLAB
MLAB
Q4 25
$-18.5M
$3.6M
Q3 25
$-12.7M
$2.5M
Q2 25
$-16.9M
$4.7M
Q1 25
$-14.9M
$-7.1M
Q4 24
$-25.4M
$-1.7M
Q3 24
$-19.4M
$3.4M
Q2 24
$-83.6M
$3.4M
Q1 24
$-17.6M
$-254.6M
Gross Margin
KORE
KORE
MLAB
MLAB
Q4 25
64.2%
Q3 25
61.5%
Q2 25
62.0%
Q1 25
61.8%
Q4 24
63.3%
Q3 24
61.3%
Q2 24
64.0%
Q1 24
62.1%
Operating Margin
KORE
KORE
MLAB
MLAB
Q4 25
-0.8%
12.2%
Q3 25
-6.1%
7.8%
Q2 25
-7.3%
5.1%
Q1 25
-3.4%
2.4%
Q4 24
-17.8%
9.2%
Q3 24
-8.2%
6.1%
Q2 24
-113.0%
9.6%
Q1 24
-9.7%
-460.6%
Net Margin
KORE
KORE
MLAB
MLAB
Q4 25
-25.0%
5.6%
Q3 25
-18.5%
4.1%
Q2 25
-23.7%
8.0%
Q1 25
-20.7%
-11.4%
Q4 24
-34.7%
-2.7%
Q3 24
-28.2%
5.9%
Q2 24
-123.2%
5.8%
Q1 24
-23.1%
-432.2%
EPS (diluted)
KORE
KORE
MLAB
MLAB
Q4 25
$-0.92
$0.65
Q3 25
$-0.64
$0.45
Q2 25
$-0.86
$0.85
Q1 25
$-0.77
$-1.30
Q4 24
$-1.29
$-0.31
Q3 24
$-1.00
$0.63
Q2 24
$-4.37
$0.62
Q1 24
$-0.93
$-47.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KORE
KORE
MLAB
MLAB
Cash + ST InvestmentsLiquidity on hand
$26.7M
$29.0M
Total DebtLower is stronger
$301.3M
$68.4M
Stockholders' EquityBook value
$-163.8M
$186.7M
Total Assets
$410.5M
$434.8M
Debt / EquityLower = less leverage
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KORE
KORE
MLAB
MLAB
Q4 25
$26.7M
$29.0M
Q3 25
$19.3M
$20.4M
Q2 25
$21.0M
$21.3M
Q1 25
$19.7M
$27.3M
Q4 24
$19.4M
$27.3M
Q3 24
$18.6M
$24.3M
Q2 24
$22.3M
$28.5M
Q1 24
$23.0M
$28.2M
Total Debt
KORE
KORE
MLAB
MLAB
Q4 25
$301.3M
$68.4M
Q3 25
$69.4M
Q2 25
$70.3M
Q1 25
$71.3M
Q4 24
$303.1M
$72.2M
Q3 24
$73.1M
Q2 24
$74.1M
Q1 24
Stockholders' Equity
KORE
KORE
MLAB
MLAB
Q4 25
$-163.8M
$186.7M
Q3 25
$-145.7M
$178.5M
Q2 25
$-133.5M
$172.5M
Q1 25
$-114.9M
$159.8M
Q4 24
$-99.6M
$155.2M
Q3 24
$-77.2M
$161.5M
Q2 24
$-57.2M
$150.7M
Q1 24
$22.3M
$145.4M
Total Assets
KORE
KORE
MLAB
MLAB
Q4 25
$410.5M
$434.8M
Q3 25
$423.4M
$430.4M
Q2 25
$432.9M
$435.7M
Q1 25
$445.1M
$433.3M
Q4 24
$455.8M
$433.3M
Q3 24
$473.9M
$454.1M
Q2 24
$487.7M
$440.4M
Q1 24
$576.6M
$446.8M
Debt / Equity
KORE
KORE
MLAB
MLAB
Q4 25
0.37×
Q3 25
0.39×
Q2 25
0.41×
Q1 25
0.45×
Q4 24
0.47×
Q3 24
0.45×
Q2 24
0.49×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KORE
KORE
MLAB
MLAB
Operating Cash FlowLast quarter
$10.4M
$18.8M
Free Cash FlowOCF − Capex
$9.4M
$18.0M
FCF MarginFCF / Revenue
12.7%
27.7%
Capex IntensityCapex / Revenue
1.5%
1.1%
Cash ConversionOCF / Net Profit
5.17×
TTM Free Cash FlowTrailing 4 quarters
$15.8M
$37.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KORE
KORE
MLAB
MLAB
Q4 25
$10.4M
$18.8M
Q3 25
$1.1M
$8.2M
Q2 25
$4.1M
$1.9M
Q1 25
$2.9M
$12.7M
Q4 24
$2.1M
$18.1M
Q3 24
$1.2M
$5.3M
Q2 24
$4.0M
$10.7M
Q1 24
$1.9M
$12.9M
Free Cash Flow
KORE
KORE
MLAB
MLAB
Q4 25
$9.4M
$18.0M
Q3 25
$879.0K
$7.1M
Q2 25
$2.8M
$884.0K
Q1 25
$2.7M
$11.9M
Q4 24
$2.0M
$17.3M
Q3 24
$973.0K
$3.5M
Q2 24
$3.1M
$9.9M
Q1 24
$1.0M
$12.3M
FCF Margin
KORE
KORE
MLAB
MLAB
Q4 25
12.7%
27.7%
Q3 25
1.3%
11.7%
Q2 25
4.0%
1.5%
Q1 25
3.8%
19.2%
Q4 24
2.7%
27.6%
Q3 24
1.4%
6.0%
Q2 24
4.6%
16.9%
Q1 24
1.4%
21.0%
Capex Intensity
KORE
KORE
MLAB
MLAB
Q4 25
1.5%
1.1%
Q3 25
0.3%
1.8%
Q2 25
1.8%
1.7%
Q1 25
0.2%
1.2%
Q4 24
0.1%
1.3%
Q3 24
0.3%
3.1%
Q2 24
1.3%
1.5%
Q1 24
1.2%
0.9%
Cash Conversion
KORE
KORE
MLAB
MLAB
Q4 25
5.17×
Q3 25
3.32×
Q2 25
0.40×
Q1 25
Q4 24
Q3 24
1.54×
Q2 24
3.17×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KORE
KORE

Io T Connectivity And Solutions Services$55.9M76%
Hardware Sales$15.4M21%
Deployment Services Professional Services Referral Services And Other$2.5M3%

MLAB
MLAB

Sterilization And Disinfection Control$24.9M38%
Biopharmaceutical Development$14.4M22%
Other$14.1M22%
Clinical Genomics$11.8M18%

Related Comparisons